Horama

Pépinière Paris Santé Cochin
27 rue du Faubourg Saint-Jacques
Sanofi
75014
France

About Horama

Horama is a clinical-stage biotech company that develops gene-therapy treatments, based on recombinant adeno-associated virus (rAAV) vectors, targeting rare inherited retinal diseases. The company's portfolio especially includes two products scheduled to enter into clinical trials in the coming months. Horama was founded in 2014 in Paris with the support of a group of scientists who had carried out one of the very first gene-therapy trials in ophthalmology, in 2011. These world-renowned cofounders (Philippe Moullier, Christian Hamel and Vasiliki Kalatzis of INSERM, and Michel Weber and Guylène Le Meur, of the University Hospital of Nantes) all have complementary skills.
YEAR FOUNDED:
2014
LEADERSHIP:
Chairman, Founder, Entrepreneur: Denis Cayet
TECHNOLOGY
Please click here for Horama's technology.
PIPELINE:
Please click here for Horama's pipeline.

10 articles about Horama

HORAMA Appoints Life Sciences Veteran Benedikt Timmerman as New Chairman

5/18/2020

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman.
BioSpace Movers & Shakers, May 8

5/8/2020

Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HORAMA Appoints Industry Veteran Ian Catchpole as Chief Scientific Officer

5/4/2020

HORAMA, a clinical stage gene therapy company in ophthalmology, announced the appointment of Dr. Ian Catchpole as its Chief Scientific Officer.
BioSpace Global Roundup, March 19

3/19/2020

Companies from across the globe provide updates on their business operations and pipeline development.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

3/18/2020

Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023
BioSpace Movers & Shakers, March 13

3/13/2020

Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.
HORAMA Strengthens Its Management Team With the Appointment of Rodolphe Clerval as Chief Business Officer (CBO)

3/11/2020

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that Rodolphe Clerval has been appointed as Chief Business Officer.
Horama Raises €19 Million in a Series B Financing Round

11/8/2017

This fundraising was intended to finance the development of the HORA-PDE6B project, including the start of its clinical phase, which has just been authorised by the French regulatory bodies.
Horama Granted Authorization To Conduct Phase I/II Clinical Study For HORA-PDE6B, In Retinitis Pigmentosa (RP)

10/11/2017
Horama Granted Orphan Drug Designation (ODD) In U.S. For Drug Candidate HORA-RLBP1

7/11/2017